Democritus University of Thrace (DUTH)
Μελέτη μοριακών σηματοδοτικών μηχανισμών επαγωγής της κυτταρικής επιβίωσης και αποδιαφοροποίησης στον καρκίνο
Abstract
dc:descriptionPurposeIn the last decade various high-throughput methodologies have generated enormous volumes of molecular data, valuable for the clinical evaluation, advancing translational research in various areas, in particular in oncology. Indeed, transcriptome profiling technologies have unraveled significant genomic alterations in specific cancer types like colorectal cancer, and enabled the characterization of causal genes and important gene signatures. However, the identification of a small number of genes with a strong biomarker functionality regarding Colorectal Cancer (CRC) remains challenging, mainly due to the great genetic heterogeneity of the disease. In this direction, the introduction of composite signatures derived from multiple layers of molecular and clinical dissection may resolve the problems of heterogeneity and improve robust disease stratification. MethodsIn this PhD thesis we propose a powerful generic methodology for the integrative analysis of highly complex clinical data, through inference of robust, composite signatures. We showcase the application of this integrative analytical framework to colorectal cancer, regarding the joint analysis of CRC datasets, encompassing transcriptomic data and positron emission tomography (PET) measurements. The former comprises two microarray datasets from different platforms regarding overall 30 patients (60 samples) of the German Cancer Research Center coupled by their F-18-Fluorodeoxyglucose (FDG) PET kinetic analysis profiles, using tracer kinetic analysis measurements. Our analysis utilized R statistical software/Bioconductor scripts, along with the BioInfoMiner gene analytics platform of e-NIOS Applications.ResultsTranscriptomic and PET data feature sets, were evaluated for their discrimination performance between primary colorectal adenocarcinomas and adjacent normal mucosa. Computational analysis based on semantics processing, multivariate analysis, data mining and dimensionality reduction techniques was performed for derivation and analysis of biomarker signatures, which were further evaluated using an independent CRC TCGA RNA-seq dataset. A composite signature, combining gene expression and PET data, was derived and displayed improved classification performance. Correlation analysis between PET and transcriptomic data, revealed a set of 22 PET-associated genes implicated in distinct metabolic processes. Finally, an R/shiny application was developed to perform drug repositioning and propose putative therapeutic interventions for CRC, based on the phase Ι library of integrated network-based cellular signatures (LINCS-L1000) dataset, using as an input a subset of 94 linker genes with pivotal role in the cross-talk among distinct molecular pathways implicated in tumor progression. The results of the pharmacogenomics analysis suggested the drug fedratinib as a putative therapeutic intervention in HT-29 colon adenocarcinoma cell line. Fedratinib is an inhibitor of Janus kinase 2 (JAK-2), originally developed for the treatment of patients with rare bone marrow cancers and it has been also been tested in clinical trials (myelofibrosis). In vitro validation experiments showed fedratinib (TG101348) exerts comparable or better anti-proliferation effect on colon cancer cell lines than irinotecan which is widely used in the treatment of colorectal cancer.ConclusionsThis work represents an effort for the integrative, multilayered, signature-oriented analysis of CRC, in the context of radio-genomics, inferring a composite signature with promising results for patient epidemiological stratification. Further elucidation on the interrelationships between genes and PET variables hold the promise for development of non-invasive approaches, regarding the timely monitoring and the rational therapeutic administration in CRC. This generic framework can also be expanded to other types of cancers with high metabolic reprogramming, such as breast and lung cancer, while additional layers of -omics technologies could be integrated for the elucidation of the heterogeneity among different patients for personalized medicine.
Degree
thesis:*- Grantor dc:publisher
- Democritus University of Thrace (DUTH)
- Year dc:date
- 2019
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Vlachavas, Efstathios-Iason
- Βλαχάβας, Ευστάθιος-Ιάσων
Subjects
dc:subject × 17- Καρκίνος του παχέος εντέρου (CRC)
- Τεχνολογίες υψηλής απόδοσης
- Μεταφραστική έρευνα
- Μικροσυστοιχίες DNA
- Τεχνολογίες αλληλούχισης νέας γενιάς
- Σύνθετοι βιοδείκτες
- Colorectal cancer
- Translational bioinformatics
- Radiogenomics
- 18F-FDG PET
- Microarray analysis
- RNA-Seq analysis
- Multi-Omics data integration
- Ιατρική και Επιστήμες Υγείας
- Επιστήμες Υγείας
- Medical and Health Sciences
- Health Sciences
Rights
dc:rights- Statement dc:rights
-
- BY_NC_ND
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/46398